Taken together these results suggest that p53 inhibits DPYD expression and indicate that polymorphisms of the TP53 gene could potentially indirectly alter systemic bioavailability of 5-FU that may impact the efficacy of 5-FU in cancer therapy. The gene discussed is DPYD; the disease is cancer.